How to buy Kamada stock (KMDA)

Kamada is a drug manufacturers - specialty & generic business based in the US. Kamada shares (KMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.90 – an increase of 0.51% over the previous week. Kamada employs 378 staff and has a trailing 12-month revenue of around $154.6 million.

Our top picks for where to buy Kamada stock

Buy Kamada stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kamada stock price (NASDAQ: KMDA)

Use our graph to track the performance of KMDA stocks over time.

Kamada shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$5.90
52-week range	$4.74 - $6.53
50-day moving average more info button	$5.74
200-day moving average more info button	$5.52
Wall St. target price	$14.67
PE ratio more info button	21.4815
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.27

Is it a good time to buy Kamada stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kamada price performance over time

Historical closes compared with the close of $5.85 from 2024-12-19

1 week (2024-12-13)	-0.34%
1 month (2024-11-21)	5.85
3 months (2024-09-20)	9.14%
6 months (2024-06-21)	22.38%

1 year (2023-12-21)	-1.85%
2 years (2022-12-21)	43.73%
3 years (2021-12-21)	6.63
5 years (2019-12-20)	7.01

Is Kamada stock undervalued or overvalued?

Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Kamada's P/E ratio

Kamada's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Kamada shares trade at around 21x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Kamada's PEG ratio

Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Kamada's EBITDA

Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $28.4 million.

The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.

Kamada financials

Revenue TTM	$154.6 million
Operating margin TTM	13.28%
Gross profit TTM	$46.7 million
Return on assets TTM	3.16%
Return on equity TTM	7.05%
Profit margin	9.75%
Book value	$4.25
Market Capitalization more info button	$333.5 million

TTM: trailing 12 months

Kamada share dividends

We're not expecting Kamada to pay a dividend over the next 12 months.

Kamada share price volatility

Over the last 12 months, Kamada's shares have ranged in value from as little as $4.74 up to $6.5291. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.195. This would suggest that Kamada's shares are less volatile than average (for this exchange).

Kamada overview

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. .

Frequently asked questions

What percentage of Kamada is owned by insiders or institutions?
Currently 7.312% of Kamada shares are held by insiders and 50.099% by institutions. How many people work for Kamada?
Latest data suggests 378 work at Kamada. When does the fiscal year end for Kamada?
Kamada's fiscal year ends in December. Where is Kamada based?
Kamada's address is: 2 Holzman Street, Rehovot, Israel, 7670402 What is Kamada's ISIN number?
Kamada's international securities identification number is: IL0010941198 What is Kamada's CUSIP number?
Kamada's Committee on Uniform Securities Identification Procedures number is: M6240T109